Zorbium™ (buprenorphine transdermal solution)
Zorbium™ (buprenorphine transdermal solution)
One in-clinic dose of Zorbium provides four days of continuous post-op pain control for at-home comfort.
The only FDA-approved long-acting transdermal buprenorphine for cats
4 days of continuous post-op pain control
Innovative, long-acting technology and convenient dosing
Proven effective and safe
Administered once in-clinic, Zorbium removes the need to administer repeat injections or dispense buprenorphine during the critical first few days after surgery.
Zorbium also reduces the challenges of administering pain medications at home and helps limit the risk of opioid misuse by pet owners.
See SAFETY INFORMATION tab for prescribing information including the Boxed Human Warning.
Innovative, long-acting technology
Applied transdermally, Zorbium continually releases buprenorphine into systemic circulation for 4 days.
Apply 1 to 2 hours before surgery
Dries rapidly after application
Absorbs and forms a depot within skin
A user safety study confirmed no risk to adults or children with direct exposure to the dry application site (30 minutes).
Wear impermeable latex or nitrile gloves, protective glasses and a laboratory coat when applying Zorbium.
Convenient dosing
Pre-dosed tubes simplify record keeping and disposal of controlled substances.
Proven effective in client-owned cats undergoing surgery
In a prospective, double-blinded, vehicle controlled, multicenter field study, there was significantly greater treatment success with Zorbium throughout four days.
Proven safety
Adverse events in Zorbium and placebo groups occurred at a similar frequency. Most common adverse events after anesthesia include hypothermia, hyperthermia, sedation and tachypnea.
Hypothermia occurred immediately post-op in the majority of cats in both groups.
Tachypnea occured at a higher rate in cats receiving placebo versus Zorbium, possibly related to uncontrolled pain.
No sedation observed with Zorbium beyond 1 hr after anesthetic recovery.
No dysphoria observed with Zorbium beyond 3 hrs after anesthetic recovery.
Zorbium did not affect
Urination/Defecation
Appetite/Body weight
Quality of anesthetic recovery
Body temperature should be monitored postoperatively. Most common adverse reactions during anesthesia were hypothermia, hypotension, and hypertension, and after anesthetic recovery were hypothermia, hyperthermia, and sedation.
Stay in control of opioid analgesia
Zorbium provides reassurance to veterinarians and pet owners during the critical first 4 days following surgery.
One in-clinic dose, administered by you
Limits opioid misuse opportunities by pet owners
Reassurance patients have pain relief on board
How to get Zorbium
Incorporate Zorbium into your postoperative pain protocol today.
Contact your local Elanco rep or distributor rep- Call Elanco at 1-888-545-5973
Zorbium® (buprenorphine transdermal solution) Resources
Zorbium Master Detailer
Indication
ZORBIUM is indicated for the control of postoperative pain associated with surgical procedures in cats.
Important Safety Information
Before using ZORBIUM (buprenorphine transdermal solution), read the entire package insert including the Boxed Human Warning. ZORBIUM contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse, and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of ZORBIUM. Serious, life-threatening, or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ZORBIUM. ZORBIUM should only be administered by veterinarians or veterinarian technicians who are trained in the handling of potent opioids. Accidental exposure to even one tube of ZORBIUM, especially in children, can result in a fatal overdose. ZORBIUM is for topical application in cats only. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site. Do not administer to cats with a known hypersensitivity to buprenorphine hydrochloride, any inactive ingredients of ZORBIUM or known intolerance to opioids. Most common adverse reactions during anesthesia were hypothermia, hypotension, and hypertension, and after anesthetic recovery were hypothermia, hyperthermia, and sedation. The safe use of ZORBIUM has not been evaluated in debilitated cats, those with renal, hepatic, cardiac or respiratory disease, pregnant lactating, breeding, in cats younger than four months old or <2.6 lbs or >16.5 lbs. Click to view full product label for additional product safety information.
